Abstract
CareDx will report its quarterly results on July 30, 2026, Post Market, with the market looking for revenue of 114.04 million US dollars, adjusted EPS of 0.23, and EBIT of 10.95 million US dollars; investors are watching mix shifts after the Lab Products divestiture and early integration of Naveris.Market Forecast
Consensus for the current quarter points to revenue of 114.04 million US dollars, implying 25.85% year-over-year growth, adjusted EPS of 0.23 with 94.54% year-over-year growth, and EBIT of 10.95 million US dollars with 536.33% year-over-year growth. Forecasts for gross margin and net income margins have not been disclosed by the company and are therefore omitted here.The company’s core testing operations remain the primary revenue engine, with management signaling a continued emphasis on precision medicine testing and digital offerings post the Lab Products divestiture. Within the portfolio, transplant surveillance testing appears set to drive the most near-term contribution, with 91.40 million US dollars in last quarter revenue from Testing Services; while segment-level year-over-year growth was not disclosed, company revenue grew 38.99% in the same period, offering a supportive backdrop.
Last Quarter Review
In the previous quarter, CareDx delivered revenue of 117.70 million US dollars (up 38.99% year over year), a gross profit margin of 71.43%, GAAP net profit attributable to the parent company of 2.81 million US dollars, a net profit margin of 2.39%, and adjusted EPS of 0.34 (up 277.78% year over year).A key highlight was the bottom-line inflection versus internal and external comparisons: adjusted EPS of 0.34 topped the prior consensus by 0.21, and net profit improved sequentially with a 168.38% quarter-on-quarter rise. Main business performance was anchored by Testing Services at 91.40 million US dollars, complemented by Collaboration and Licensing at 15.96 million US dollars and Products at 10.35 million US dollars, underscoring the revenue concentration in the testing franchise.
Current Quarter Outlook (with major analytical insights)
Precision Medicine Testing Services
Testing Services is expected to remain the largest revenue contributor this quarter, supported by demand for transplant surveillance assays and stable clinical adoption trends exiting the prior period. The forecasted company revenue of 114.04 million US dollars, together with management’s continued focus on core testing and digital solutions, suggests volumes and mix tied to surveillance assays should continue to shape both top line and margin outcomes. With gross margins last quarter at 71.43%, this high-value testing mix remains central to profitability, although no explicit margin outlook has been issued for the current quarter.Near-term commentary will likely center on ordering cadence, payer dynamics, and early effects from portfolio streamlining following the sale of the Lab Products business. Although the finalized Medicare Local Coverage Determination for solid organ allograft rejection is slated to take effect on August 30, 2026, expectations for improved reimbursement clarity are feeding into sentiment; any management color on pre-effective-date trends and anticipated ramp cadence will be important for modeling the second half. In parallel, operating leverage remains a swing factor: last quarter’s EBIT of 16.58 million US dollars and the current quarter forecast of 10.95 million US dollars imply that seasonality, investment cadence, and revenue mix will shape earnings conversion in the short run.
The company’s April 29, 2026, update that raised full-year 2026 revenue expectations to a range of 447.00–465.00 million US dollars (above prior street figures) remains a crucial context for investors calibrating quarterly run-rates. Given the prior-quarter revenue beat and the significantly higher year-over-year growth embedded in the current quarter’s EPS estimate, attention will be paid to whether test volume growth and price/mix can sustain the elevated revenue trajectory while maintaining disciplined operating expense growth.
Oncology Optionality via Naveris
CareDx closed the acquisition of Naveris in early July 2026, bringing blood-based tests for virus-mediated cancers into the portfolio. This expansion does not materially alter the core transplant testing narrative in the current quarter’s reported numbers, but it enhances optionality for future revenue streams and technology synergies. Management is likely to be asked about timelines for integration, go-to-market plans, and the expected near- and medium-term operating expense impacts as the team scales clinical and commercial resources.The oncology addition can create a second pillar of growth that diversifies future revenue beyond existing testing use cases. That said, the contribution to the current quarter will be limited by timing, with more measurable effects expected in subsequent periods as the acquired programs integrate into the commercial infrastructure. Investors should expect management to frame initial objectives in terms of validating clinical pathways, reimbursement milestones, and channel leverage, rather than near-term revenue, with more detailed goals likely to surface as integration progresses.
Over the balance of the year, the key monitorables will include pilot adoption metrics, development and validation updates, and how the oncology pipeline fits into the company’s existing data and digital platforms. As those pieces slot into place, this segment could increasingly inform the longer-term EBIT trajectory and support valuation frameworks that prize pipeline visibility alongside core cash-generation capabilities.
Key Stock Price Drivers This Quarter
Portfolio reshaping and capital allocation headlines provide a clear near-term stock narrative. The company announced on July 1, 2026, the closing of its Lab Products business sale to Eurobio Scientific, valued at 171.20 million US dollars. While the immediate quarter’s P&L may include transition effects, investors will be focused on how divestiture proceeds and cost realignment support the core testing and digital strategy. This shift should gradually simplify the business model and may contribute to steadier margin profiles, contingent on core volume trends.The finalization of Medicare coverage policy for transplant surveillance testing, expected to become effective on August 30, 2026, is a significant policy milestone. Although the effective date lies just beyond the current quarter’s close, management commentary regarding expected utilization trends and provider readiness could influence sentiment around second-half revenue and EBIT. Any signals on billing cycle improvements or days sales outstanding within the accounts receivable profile will be closely watched as a corroborating indicator of payor dynamics.
Leadership changes may also be part of the investment discussion this quarter. On February 24, 2026, the company named Keith Kennedy as Chief Operating Officer and Chief Financial Officer, setting up an opportunity for renewed operational benchmarks, expense discipline, and post-divestiture resource allocation. Taken together with the raised full-year revenue outlook provided on April 29, 2026, investors will assess whether the quarterly run-rate and cost roadmap align with those full-year ambitions, particularly given the expected year-over-year step-up embedded in the current quarter’s EPS and EBIT forecasts.
Analyst Opinions
Bullish views predominate among recently published opinions, with two Buy ratings versus no Sell ratings and one Hold. BTIG’s Mark Massaro reiterated a Buy rating with a 26.00 US dollars price target, citing a combination of growth prospects, discounted valuation at the time of the report, and optionality from the oncology expansion. Stephens also reaffirmed a Buy rating with a 28.00 US dollars price target, highlighting execution and the improving medium-term setup.The bullish camp’s thesis integrates three elements from recent company developments. First, the quarterly cadence has reaccelerated: last quarter’s revenue of 117.70 million US dollars grew 38.99% year over year and handily surpassed prior expectations, while adjusted EPS of 0.34 exceeded earlier estimates by 0.21. Second, policy momentum is turning more supportive, with the final coverage determination expected to take effect on August 30, 2026, laying the groundwork for steadier reimbursement across kidney, heart, and lung surveillance. While the effective date falls just after the to-be-reported period, investors anticipate management will articulate a trajectory for second-half utilization that links coverage clarity to testing volumes. Third, portfolio sharpening via the 171.20 million US dollars Lab Products sale and the closing of the Naveris acquisition provides a cleaner focus on high-margin testing and new clinical adjacencies.
Within this bullish framework, analysts have framed the current quarter’s guideposts as follows: revenue of 114.04 million US dollars with 25.85% year-over-year growth, adjusted EPS of 0.23 with 94.54% year-over-year growth, and EBIT of 10.95 million US dollars with 536.33% year-over-year growth. Because the company has not provided explicit margin guidance for the quarter, bullish analysts emphasize volume and mix drivers in the core testing business as the most actionable signals. They also point to management’s April 29, 2026, full-year revenue outlook of 447.00–465.00 million US dollars as a benchmark for assessing the sustainability of the current revenue trajectory through the second half.
Analysts aligned with the bullish view anticipate that commentary on the post-divestiture operating model will reinforce a path to disciplined expense growth, with proceeds and cost savings redirected to the testing and digital ecosystem where past gross margins of 71.43% underline a structurally favorable unit economics model. They expect management to discuss how the operational changes, combined with the upcoming reimbursement clarity, may support a more predictable revenue stream, which in turn could help stabilize quarter-to-quarter earnings variability. On oncology, bullish views treat the Naveris integration as an option on future growth rather than a core driver of this quarter’s numbers, but they underscore the strategic value of expanding into blood-based viral oncology testing fields that can draw on overlapping capabilities in clinical testing, data, and physician channel engagement.
Overall, the majority view holds that the combination of supportive revenue momentum, impending reimbursement policy clarity, and tighter portfolio focus creates favorable conditions into the July 30, 2026, Post Market print. The key tests for this outlook will be whether management’s revenue and earnings cadence matches the elevated year-over-year comparisons embedded in forecasts, and whether commentary on demand, billing, and integration confirms the building blocks for second-half execution.
Comments